Thirty-eight percent of clinical research sites say protocol complexity determines whether they take on a study at all, which means sponsors are losing site capacity before enrollment ever opens. WCG’s 2026 Clinical Research Site Challenges Report puts the number in sharper relief: 66% of sites name protocol complexity as the single biggest driver of overall trial complexity. Those two figures describe a system where design decisions made in a conference room directly shrink the pool of sites willing to participate.

The scale of that complexity has grown steadily over two decades. Tufts CSDD data show the number of distinct procedures per trial visit tripled between 2001 and 2020, and eligibility criteria rose more than 60% over the same period. Sites absorbing that burden today do so against a backdrop of flat or shrinking operational resources, which is why a complicated protocol now carries a real risk of rejection, not just slower startup.

WCG’s response is to move the diagnostic earlier. Its ClinSphere Trial IntelX platform and Study Ready Feasibility Services are built to surface operational risk at the design stage, before a protocol reaches sites. The pitch is straightforward: use real-world site performance data to model how a given design will behave in practice, flag amendment risk while changes are still cheap, and estimate enrollment impact before the study is locked. That sequence matters because amendments that arrive after sites are activated force retraining, re-consent, and regulatory submissions, each of which extends the timeline and erodes site goodwill. Roughly two-thirds of senior biopharma executives already report using real-world data to inform protocol design, so the approach is not novel, but moving it upstream into feasibility decisions rather than post-hoc analysis is the specific shift WCG is advocating.

The practical test for this argument is amendment frequency. If predictive design tools reduce the number of mid-study amendments at sites already stretched thin, site acceptance rates for complex studies should follow. That is the number worth tracking as adoption of these tools widens.

Source link: https://www.wcgclinical.com/insights/reducing-site-burden-starts-with-better-protocol-design/

Website | + posts

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.